Organogenesis Holdings Inc. (ORGO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORGO POWR Grades
- ORGO scores best on the Value dimension, with a Value rank ahead of 99.58% of US stocks.
- ORGO's strongest trending metric is Value; it's been moving up over the last 177 days.
- ORGO ranks lowest in Momentum; there it ranks in the 10th percentile.
ORGO Stock Summary
- With a price/earnings ratio of 5.62, ORGANOGENESIS HOLDINGS INC P/E ratio is greater than that of about just 15.2% of stocks in our set with positive earnings.
- Over the past twelve months, ORGO has reported earnings growth of -41.95%, putting it ahead of 26.2% of US stocks in our set.
- In terms of volatility of its share price, ORGO is more volatile than 77.59% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ORGANOGENESIS HOLDINGS INC, a group of peers worth examining would be IOSP, JOUT, BRC, MGIC, and TBLT.
- Visit ORGO's SEC page to see the company's official filings. To visit the company's web site, go to organogenesis.com.
ORGO Valuation Summary
- ORGO's price/sales ratio is 0.9; this is 80.65% lower than that of the median Healthcare stock.
- Over the past 70 months, ORGO's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ORGO.
ORGO's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- ORGO has a Quality Grade of B, ranking ahead of 77.36% of graded US stocks.
- ORGO's asset turnover comes in at 1.426 -- ranking 12th of 681 Pharmaceutical Products stocks.
- VRTX, ACOR, and TPST are the stocks whose asset turnover ratios are most correlated with ORGO.
The table below shows ORGO's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
ORGO Stock Price Chart Interactive Chart >
ORGO Price/Volume Stats
|Current price||$3.37||52-week high||$15.12|
|Prev. close||$3.22||52-week low||$3.08|
|Day high||$3.40||Avg. volume||1,097,177|
|50-day MA||$4.41||Dividend yield||N/A|
|200-day MA||$6.38||Market Cap||441.09M|
Organogenesis Holdings Inc. (ORGO) Company Bio
Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, surgical, and sports medicine markets. Organogenesis Holdings serves customers in the United States and Switzerland.
Most Popular Stories View All
ORGO Latest News Stream
|Loading, please wait...|
ORGO Latest Social Stream
View Full ORGO Social Stream
Latest ORGO News From Around the Web
Below are the latest news stories about ORGANOGENESIS HOLDINGS INC that investors may wish to consider to help them evaluate ORGO as an investment opportunity.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.
In this article, we discuss the 10 best 52-week low small-cap stocks to buy now. If you want to skip our discussion on the overall economic environment in the US, go to 5 Best 52-Week Low Small-Cap Stocks to Buy Now. The US stock markets have come under pressure as inflation rose faster than expected […]
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from Septem
Organogenesis Holdings Inc (NASDAQ: ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal. Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance. Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these compl
PuraPly MZ is an Innovative Product for Complex Surgical WoundsCANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. PuraPly MZ leverages the innovative properties of our PuraPly technology engineered into a micronized (powdered) form to provide surgeons with an option for complex surgical wou
ORGO Price Returns
Continue Researching ORGOWant to see what other sources are saying about Organogenesis Holdings Inc's financials and stock price? Try the links below:
Organogenesis Holdings Inc (ORGO) Stock Price | Nasdaq
Organogenesis Holdings Inc (ORGO) Stock Quote, History and News - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock Price and Basic Information | MarketWatch